ADC Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . ADC Therapeutics SA
ADCT Stock  USD 1.83  0.08  4.57%   
ADC Therapeutics financial statements provide useful quarterly and yearly information to potential ADC Therapeutics SA investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on ADC Therapeutics financial statements helps investors assess ADC Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting ADC Therapeutics' valuation are summarized below:
Gross Profit
-59.9 M
Profit Margin
(3.00)
Market Capitalization
176.9 M
Enterprise Value Revenue
0.2755
Revenue
70.7 M
There are currently one hundred twenty fundamental measures for ADC Therapeutics that can be evaluated and compared over time across peers in the sector. All traders should validate ADC Therapeutics' latest fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 148.2 M in 2025. Enterprise Value is likely to gain to about (20.3 M) in 2025

ADC Therapeutics Total Revenue

50.08 Million

Check ADC Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ADC Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 5 M, Depreciation And Amortization of 2.7 M or Interest Expense of 55.9 M, as well as many indicators such as Price To Sales Ratio of 2.13, Dividend Yield of 0.0 or Days Sales Outstanding of 228. ADC financial statements analysis is a perfect complement when working with ADC Therapeutics Valuation or Volatility modules.
  
Check out the analysis of ADC Therapeutics Correlation against competitors.

ADC Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets375.5 M408 M277.8 M
Slightly volatile
Other Current Liabilities33.5 M58.2 M23.1 M
Slightly volatile
Total Current Liabilities48.6 M77.8 M33.6 M
Slightly volatile
Property Plant And Equipment Net19.5 M18.6 M5.9 M
Slightly volatile
Current Deferred Revenue4.5 M4.3 M2.4 M
Slightly volatile
Accounts Payable9 M17.9 M6.6 M
Slightly volatile
Cash298.6 M320.4 M228.3 M
Slightly volatile
Non Current Assets Total40.1 M21.3 M23.5 M
Slightly volatile
Non Currrent Assets Other509 K817.6 K364.5 K
Slightly volatile
Cash And Short Term Investments298.6 M320.4 M228.3 M
Slightly volatile
Net Receivables19.8 M29 M14.3 M
Slightly volatile
Liabilities And Stockholders Equity375.5 M408 M277.8 M
Slightly volatile
Non Current Liabilities Total525.7 M500.7 M147.6 M
Slightly volatile
Other Current Assets9.9 M18.8 M6.9 M
Slightly volatile
Other Stockholder Equity827.5 M1.4 B608.3 M
Slightly volatile
Total Liabilities607.4 M578.5 M183.3 M
Slightly volatile
Total Current Assets335.4 M386.7 M254.3 M
Slightly volatile
Intangible Assets9.7 M16.5 M7.5 M
Slightly volatile
Common Stock4.5 M8.4 M3 M
Slightly volatile
Other Liabilities36.3 M29.1 M19 M
Slightly volatile
Net Tangible Assets64.4 M67.8 M183.4 M
Slightly volatile
Other Assets1.091.153.7 M
Slightly volatile
Common Stock Total Equity7.6 M7.3 M3 M
Slightly volatile
Common Stock Shares Outstanding75.7 M94 M66.5 M
Slightly volatile
Capital Surpluse361.8 M407 M443.8 M
Slightly volatile
Inventory19.5 M18.6 M6 M
Slightly volatile
Property Plant And Equipment Gross24.6 M23.5 M7.3 M
Slightly volatile
Net Working Capital305.5 M308.9 M266.9 M
Slightly volatile
Property Plant Equipment6.4 M11.5 M4.4 M
Slightly volatile
Capital Stock5.9 M8.4 M3.1 M
Slightly volatile
Short and Long Term Debt Total85.9 M143 M41.5 M
Slightly volatile
Capital Lease Obligations7.9 M13.4 M6.4 M
Slightly volatile
Short Term Debt1.3 M1.3 M1.9 M
Pretty Stable
Long Term Debt88.6 M101.5 M107.1 M
Slightly volatile
Long Term Investments1.4 M1.5 M37.7 M
Slightly volatile
Short and Long Term Debt8.3 M14.3 M5.9 M
Slightly volatile
Non Current Liabilities Other10.7 M10.2 M2.1 M
Slightly volatile
Deferred Long Term Liabilities871.8 K1.1 M715.6 K
Slightly volatile

ADC Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income5 M7.6 M3.2 M
Slightly volatile
Depreciation And Amortization2.7 M3.8 M1.6 M
Slightly volatile
Interest Expense55.9 M53.3 M15 M
Slightly volatile
Selling General Administrative57.9 M55.7 M33.5 M
Slightly volatile
Other Operating Expenses224.1 M270.9 M161 M
Slightly volatile
Research Development145.6 M146.2 M113.6 M
Slightly volatile
Cost Of Revenue2.2 M2.3 M57.8 M
Slightly volatile
Total Operating Expenses222.8 M268 M160.2 M
Slightly volatile
Reconciled Depreciation2 M3.3 M1.3 M
Slightly volatile
Selling And Marketing Expenses58.7 M66.1 M34.9 M
Slightly volatile

ADC Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation25.7 M15.5 M13.2 M
Slightly volatile
Begin Period Cash Flow297.5 M375.4 M223.2 M
Slightly volatile
Depreciation2.1 M3.8 M1.3 M
Slightly volatile
Capital Expenditures3.5 M3.7 M3.2 M
Pretty Stable
End Period Cash Flow318.7 M320.4 M281.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.132.24631
Slightly volatile
Days Sales Outstanding228152300
Slightly volatile
Stock Based Compensation To Revenue0.210.220.6039
Very volatile
Capex To Depreciation1.081.135.4108
Slightly volatile
Inventory Turnover0.170.18155
Slightly volatile
Days Of Inventory On Hand2.2 K2.1 K766
Slightly volatile
Payables Turnover0.180.198.8123
Slightly volatile
Sales General And Administrative To Revenue0.760.83.4517
Slightly volatile
Research And Ddevelopement To Revenue2.02.134.0862
Slightly volatile
Capex To Revenue0.05050.05321.1016
Slightly volatile
Cash Per Share3.333.074.1751
Pretty Stable
Days Payables Outstanding2.1 K2 K738
Slightly volatile
Income Quality0.940.570.8302
Pretty Stable
Intangibles To Total Assets0.02440.02710.0251
Slightly volatile
Net Debt To EBITDA1.791.212.1592
Slightly volatile
Current Ratio9.465.7211.1139
Slightly volatile
Receivables Turnover2.182.491.6937
Slightly volatile
Graham Number12.912.5912.0025
Very volatile
Capex Per Share0.05130.04530.0499
Pretty Stable
Revenue Per Share0.540.770.377
Slightly volatile
Interest Debt Per Share1.021.880.6262
Slightly volatile
Debt To Assets0.330.320.1146
Slightly volatile
Operating Cycle2.3 K2.2 K1 K
Slightly volatile
Days Of Payables Outstanding2.1 K2 K738
Slightly volatile
Ebt Per Ebit0.851.061.0128
Slightly volatile
Quick Ratio9.335.4411.0301
Slightly volatile
Net Income Per E B T0.821.111.0058
Very volatile
Cash Ratio8.834.7310.435
Slightly volatile
Days Of Inventory Outstanding2.2 K2.1 K766
Slightly volatile
Days Of Sales Outstanding228152300
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.181.0477
Slightly volatile
Fixed Asset Turnover4.143.883.3217
Slightly volatile
Debt Ratio0.330.320.1146
Slightly volatile
Price Sales Ratio2.132.24631
Slightly volatile
Asset Turnover0.190.180.0719
Slightly volatile

ADC Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap148.2 M156 M1.4 B
Slightly volatile

ADC Fundamental Market Drivers

Cash And Short Term Investments278.6 M

ADC Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About ADC Therapeutics Financial Statements

ADC Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although ADC Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in ADC Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on ADC Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue4.3 M4.5 M
Total Revenue80 M50.1 M
Cost Of Revenue2.3 M2.2 M
Stock Based Compensation To Revenue 0.22  0.21 
Sales General And Administrative To Revenue 0.80  0.76 
Research And Ddevelopement To Revenue 2.10  2.00 
Capex To Revenue 0.05  0.05 
Revenue Per Share 0.77  0.54 
Ebit Per Revenue(2.15)(2.26)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ADC Stock Analysis

When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY